Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Oncosec Medical (ONCS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,656
  • Shares Outstanding, K 6,481
  • Annual Sales, $ 0 K
  • Annual Income, $ -39,140 K
  • 60-Month Beta 2.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/19
See More
  • Average Estimate -1.37
  • Number of Estimates 1
  • High Estimate -1.37
  • Low Estimate -1.37
  • Prior Year -1.80
  • Growth Rate Est. (year over year) +23.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.34 +6.41%
on 05/24/19
5.90 -57.80%
on 04/25/19
-3.31 (-57.07%)
since 04/24/19
3-Month
2.34 +6.41%
on 05/24/19
7.50 -66.80%
on 04/17/19
-3.51 (-58.50%)
since 02/22/19
52-Week
2.34 +6.41%
on 05/24/19
19.60 -87.30%
on 11/01/18
-13.41 (-84.34%)
since 05/24/18

Most Recent Stories

More News
OncoSec Medical (ONCS) Looks Good: Stock Adds 6.6% in Session

OncoSec Medical (ONCS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

ANIK : 38.09 (+2.17%)
ONCS : 2.49 (-3.11%)
OncoSec Medical Incorporated Prices $11,000,000 Public Offering

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a late-stage cancer biotechnology company developing intratumoral gene-delivery immunotherapies, today announced the pricing of an underwritten public...

ONCS : 2.49 (-3.11%)
OncoSec to Present at ThinkEquity Conference 2019

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chief Executive Officer...

ONCS : 2.49 (-3.11%)
OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to it's Board of Directors

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced the appointment of Margaret R. Dalesandro, Ph.D., to the Company's Board...

ONCS : 2.49 (-3.11%)
OncoSec Announces Triple Combination Immunotherapy Clinical Trial Of TAVO(TM), Epacadostat And KEYTRUDA® In Squamous Cell Head And Neck (SCCHN) Cancer

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced a triple combination clinical trial of OncoSec's TAVO(TM), epacadostat, and...

ONCS : 2.49 (-3.11%)
OncoSec Announces Collaborative Research Agreement in HER2+ Breast Cancer Evaluating the Use of TAVO(TM) in Combination with Plasmid DNA Vaccines with a World Leading Academic Medical Center

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, and Duke University School of Medicine, today announced that they have entered into a collaborative...

ONCS : 2.49 (-3.11%)
OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced the development of a new, propriety technology to potentially treat pancreatic,...

ONCS : 2.49 (-3.11%)
OncoSec to Present at H.C. Wainwright Global Life Sciences Conference

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that Dan O'Connor, President, Director & Chief Executive Officer, will present...

ONCS : 2.49 (-3.11%)
OncoSec's KOL Symposium Sheds New Light on the Importance of IL-12 Use Via OncoSec's Technology and Provides Updates on TAVO's Clinical Progress

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, provided an update on recent pipeline and regulatory progress during a Key Opinion Leader...

ONCS : 2.49 (-3.11%)
Biotech Firms Strive to Combat the Growing Burden of Diseases With Innovative Technologies

NEW YORK, April 4, 2019 The global burden of diseases continues to grow each year, despite various ongoing medical advancements. In 2017, the Institute for Health Metrics and Evaluation (IHME) said in...

SRNE : 3.50 (-1.41%)
ARQL : 7.53 (+2.59%)
ONCS : 2.49 (-3.11%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0102 (-19.69%)
SNSS : 0.94 (-10.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade ONCS with:

Business Summary

OncoSec Medical Incorporated is a biomedical company engaged in the designing, development and commercialization of therapeutic oncology products. It also develops novel OMS ElectroOncology therapies and OncoSec Medical System for the treatment of solid tumors. OncoSec Medical Incorporated is based in...

See More

Key Turning Points

2nd Resistance Point 2.80
1st Resistance Point 2.65
Last Price 2.49
1st Support Level 2.34
2nd Support Level 2.18

See More

52-Week High 19.60
Fibonacci 61.8% 13.01
Fibonacci 50% 10.97
Fibonacci 38.2% 8.93
Last Price 2.49
52-Week Low 2.34

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar